Sinovac Biotech ( (SVA) ) has provided an update.
On February 8, 2025, Sinovac Biotech Ltd. received a court order from the Privy Council affirming the election of a new board of directors and invalidating the company’s poison pill agreement. As a result, trading in Sinovac’s shares, which had been halted for six years, is set to resume following the cancellation of invalid exchange shares. The new board is committed to maintaining transparency and high corporate governance standards while working with Nasdaq to ensure the continued listing of the company’s shares.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines against COVID-19, hepatitis A, enterovirus 71, varicella, influenza, and poliomyelitis. The company is known for its COVID-19 vaccine, CoronaVac, which has been approved in over 60 countries, and it continues to explore global market opportunities.
Average Trading Volume: 8,227
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $460.3M
For detailed information about SVA stock, go to TipRanks’ Stock Analysis page.